Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1004P - Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients

Date

10 Sep 2022

Session

Poster session 14

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Junhui Guo

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

J. Guo1, X. Wang2, F. Zheng2, G. Zhao2, Y. Wang2, Y. Hu2, P. Liu2, C. Ma2

Author affiliations

  • 1 Department Of Cancer, Henan Province Hospital of Traditional Chinese Medicine, 450000 - Zhengzhou/CN
  • 2 Department Of Cancer, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1004P

Background

Docetaxel is a standard second line treatment in advanced NSCLC, but the treatment effect is limited. Anlotinib was a novel oral multi-targeted tyrosine kinase inhibitor for tumor angiogenesis and proliferation, which had been licensed for treatment of considerable malignancies in China. However, limited evidence exists to show the efficacy of anlotinib monotherapy or combination therapy for patients who have progressed after first line therapy. Therefore, a retrospective study was conducted to assess whether anlotinib combination therapy could improve efficacy compared with anlotinib monotherapy therapy as second line therapy for NSCLC patients.

Methods

Pts with advanced NSCLC who received at least 2 cycles of anlotinib (8∼12mg, po, d1∼14, q3w) were recruited in this study in Henan Province Hospital of TCM. Clinical efficacy and survival data was summarized, adverse events were documented retrospectively. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR) and safety.

Results

From Jan 2020 to Aug 2021, a total of 20 eligible pts with EGFR-wild-type NSCLC were screened. Among them, 6 pts received anlotinib monotherapy and 14 were treated with anlotinib with or without anti-PD-1/chemotherapy. With a median follow-up of 8.4 months, combination therapy group showed longer PFS compared with monotherapy group (8.40m vs. 5.25m, HR = 0.72). In addition, ORR was 21.4% (3/14) in the combination therapy group versus 16.7% (1/6) in the monotherapy group and the DCR was 87.5% (14/16) in the combination therapy group versus 66.7% (4/6) in the monotherapy group. The safety profile suggested that the most common drug-related adverse events were decreased appetite, thrombocytopenia, hypertension, diarrhea, hand-foot syndrome, proteinuria and there were no ≥Grade 3 toxicities.

Conclusions

Anlotinib with or without anti-PD-1/chemotherapy resulted in longer PFS and higher ORR and DCR as second line therapy in EGFR-wild-type advanced NSCLC patients. These findings need to be further explored by randomized controlled studies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.